BETA
Your AI-Trained Oncology Knowledge Connection!
Medical oncologists share expert perspectives on treatment paradigms for patients with early-stage NSCLC and actionable mutations.
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Sunvozertinib Earns FDA Accelerated Approval in EGFR Exon 20+ NSCLC
Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.
Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting
Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.
Taletrectinib Increases Already Broad Selection of ROS1+ NSCLC Therapies
Jorge Nieva, MD, discusses how clinical experience has shown that taletrectinib is manageable and can elicit responses in patients with ROS1-positive non–small cell lung cancer.
Adopting Best Practices for Administering TROP2-Directed ADCs in NSCLC
Experts from Washington University in St Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.
Zidesamtinib May Yield Meaningful Outcomes in Advanced ROS1+ NSCLC
Developers plan to begin a rolling new drug application for zidesamtinib as a treatment for this non–small cell lung cancer population in July 2025.
Dato-DXd Earns FDA Accelerated Approval in Pretreated EGFR-Mutated mNSCLC
The decision is supported by results from the phase 2 TROPION-Lung05 and phase 3 TROPION-Lung01 trials.